534 related articles for article (PubMed ID: 32117295)
1. Insights Into Lung Cancer Immune-Based Biology, Prevention, and Treatment.
Saab S; Zalzale H; Rahal Z; Khalifeh Y; Sinjab A; Kadara H
Front Immunol; 2020; 11():159. PubMed ID: 32117295
[TBL] [Abstract][Full Text] [Related]
2. [Immune Microenvironment Comparation Study between EGFR Mutant and EGFR Wild Type Lung Adenocarcinoma Patients Based on TCGA Database].
Zhu G; Li Y; Shi R; Xu S; Zhang Z; Cao P; Chen C; Liu H; Chen J
Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):236-244. PubMed ID: 33910272
[TBL] [Abstract][Full Text] [Related]
3. Early Events in the Molecular Pathogenesis of Lung Cancer.
Kadara H; Scheet P; Wistuba II; Spira AE
Cancer Prev Res (Phila); 2016 Jul; 9(7):518-27. PubMed ID: 27006378
[TBL] [Abstract][Full Text] [Related]
4. Lung Cancer and Immunity Markers.
Lim RJ; Liu B; Krysan K; Dubinett SM
Cancer Epidemiol Biomarkers Prev; 2020 Dec; 29(12):2423-2430. PubMed ID: 32856614
[TBL] [Abstract][Full Text] [Related]
5. B2M gene expression shapes the immune landscape of lung adenocarcinoma and determines the response to immunotherapy.
Zhao Y; Cao Y; Chen Y; Wu L; Hang H; Jiang C; Zhou X
Immunology; 2021 Nov; 164(3):507-523. PubMed ID: 34115389
[TBL] [Abstract][Full Text] [Related]
6. A risk model developed based on tumor microenvironment predicts overall survival and associates with tumor immunity of patients with lung adenocarcinoma.
Wu J; Li L; Zhang H; Zhao Y; Zhang H; Wu S; Xu B
Oncogene; 2021 Jul; 40(26):4413-4424. PubMed ID: 34108619
[TBL] [Abstract][Full Text] [Related]
7. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
[No Abstract] [Full Text] [Related]
8. The innate immune architecture of lung tumors and its implication in disease progression.
Milette S; Fiset PO; Walsh LA; Spicer JD; Quail DF
J Pathol; 2019 Apr; 247(5):589-605. PubMed ID: 30680732
[TBL] [Abstract][Full Text] [Related]
9. Field cancerization in non-small cell lung cancer: implications in disease pathogenesis.
Kadara H; Wistuba II
Proc Am Thorac Soc; 2012 May; 9(2):38-42. PubMed ID: 22550239
[TBL] [Abstract][Full Text] [Related]
10. The Combined Detection of Immune Genes for Predicting the Prognosis of Patients With Non-Small Cell Lung Cancer.
Tian WJ; Liu SS; Li BR
Technol Cancer Res Treat; 2020; 19():1533033820977504. PubMed ID: 33256552
[TBL] [Abstract][Full Text] [Related]
11. Clinical Significance and Immunologic Landscape of a Five-IL(R)-Based Signature in Lung Adenocarcinoma.
Fan T; Pan S; Yang S; Hao B; Zhang L; Li D; Geng Q
Front Immunol; 2021; 12():693062. PubMed ID: 34497605
[TBL] [Abstract][Full Text] [Related]
12. An Immunogram for the Cancer-Immunity Cycle: Towards Personalized Immunotherapy of Lung Cancer.
Karasaki T; Nagayama K; Kuwano H; Nitadori JI; Sato M; Anraku M; Hosoi A; Matsushita H; Morishita Y; Kashiwabara K; Takazawa M; Ohara O; Kakimi K; Nakajima J
J Thorac Oncol; 2017 May; 12(5):791-803. PubMed ID: 28088513
[TBL] [Abstract][Full Text] [Related]
13. Natural killer cell‑based immunotherapy for lung cancer: Challenges and perspectives (Review).
Zeng Y; Lv X; Du J
Oncol Rep; 2021 Nov; 46(5):. PubMed ID: 34498710
[TBL] [Abstract][Full Text] [Related]
14.
Liu L; Wang C; Li S; Qu Y; Xue P; Ma Z; Zhang X; Bai H; Wang J
Front Immunol; 2021; 12():677169. PubMed ID: 34354701
[TBL] [Abstract][Full Text] [Related]
15. Next-Generation Sequencing of Lung Cancers: Lessons Learned and Future Directions.
Devarakonda S; Masood A; Govindan R
Hematol Oncol Clin North Am; 2017 Feb; 31(1):1-12. PubMed ID: 27912825
[TBL] [Abstract][Full Text] [Related]
16. Lung Adenocarcinoma and Squamous Cell Carcinoma Gene Expression Subtypes Demonstrate Significant Differences in Tumor Immune Landscape.
Faruki H; Mayhew GM; Serody JS; Hayes DN; Perou CM; Lai-Goldman M
J Thorac Oncol; 2017 Jun; 12(6):943-953. PubMed ID: 28341226
[TBL] [Abstract][Full Text] [Related]
17. Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer.
Leonetti A; Wever B; Mazzaschi G; Assaraf YG; Rolfo C; Quaini F; Tiseo M; Giovannetti E
Drug Resist Updat; 2019 Sep; 46():100644. PubMed ID: 31585395
[TBL] [Abstract][Full Text] [Related]
18. The Immune Contexture Associates with the Genomic Landscape in Lung Adenomatous Premalignancy.
Krysan K; Tran LM; Grimes BS; Fishbein GA; Seki A; Gardner BK; Walser TC; Salehi-Rad R; Yanagawa J; Lee JM; Sharma S; Aberle DR; Spira AE; Elashoff DA; Wallace WD; Fishbein MC; Dubinett SM
Cancer Res; 2019 Oct; 79(19):5022-5033. PubMed ID: 31142513
[TBL] [Abstract][Full Text] [Related]
19. Immune evolution from preneoplasia to invasive lung adenocarcinomas and underlying molecular features.
Dejima H; Hu X; Chen R; Zhang J; Fujimoto J; Parra ER; Haymaker C; Hubert SM; Duose D; Solis LM; Su D; Fukuoka J; Tabata K; Pham HHN; Mcgranahan N; Zhang B; Ye J; Ying L; Little L; Gumbs C; Chow CW; Estecio MR; Godoy MCB; Antonoff MB; Sepesi B; Pass HI; Behrens C; Zhang J; Vaporciyan AA; Heymach JV; Scheet P; Lee JJ; Wu J; Futreal PA; Reuben A; Kadara H; Wistuba II; Zhang J
Nat Commun; 2021 May; 12(1):2722. PubMed ID: 33976164
[TBL] [Abstract][Full Text] [Related]
20. Impaired Tumor-Infiltrating T Cells in Patients with Chronic Obstructive Pulmonary Disease Impact Lung Cancer Response to PD-1 Blockade.
Biton J; Ouakrim H; Dechartres A; Alifano M; Mansuet-Lupo A; Si H; Halpin R; Creasy T; Bantsimba-Malanda C; Arrondeau J; Goldwasser F; Boudou-Rouquette P; Fournel L; Roche N; Burgel PR; Goc J; Devi-Marulkar P; Germain C; Dieu-Nosjean MC; Cremer I; Herbst R; Damotte D
Am J Respir Crit Care Med; 2018 Oct; 198(7):928-940. PubMed ID: 29518341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
